Neurokinin-1 receptor antagonists as antitumor drugs in gastrointestinal cancer: A new approach
The Saudi Journal of Gastroenterology, 2016 Gastrointestinal (GI) cancer is the term for a group of cancers affecting the digestive system. After binding to the neurokinin-1 (NK-1) receptor, the undecapeptide substance P (SP) regulates GI cancer cell proliferation and migration for invasion and ...
Miguel Muñoz, Rafael Coveñas
doaj +3 more sources
Evolving role of neurokinin 1-receptor antagonists for chemotherapy-induced nausea and vomiting [PDF]
OncoTargets and Therapy, 2018 To examine pharmacologic and clinical characteristics of neurokinin 1 (NK1)-receptor antagonists (RAs) for preventing chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy, a literature search was ...
Lee Schwartzberg
exaly +3 more sources
The Repurposing of Non-Peptide Neurokinin-1 Receptor Antagonists as Antitumor Drugs: An Urgent Challenge for Aprepitant. [PDF]
Int J Mol Sci, 2023 The substance P (SP)/neurokinin-1 receptor (NK-1R) system is involved in cancer progression. NK-1R, activated by SP, promotes tumor cell proliferation and migration, angiogenesis, the Warburg effect, and the prevention of apoptosis.
Coveñas R +3 more
europepmc +2 more sources
Neurokinin 1 Receptor Antagonists for Pruritus. [PDF]
Drugs, 2021 Pruritus, commonly known as itch, is a very common symptom in numerous dermatological disorders and systemic diseases. It can manifest as acute, or when lasting longer than 6 weeks, it is considered chronic and can lead to significant distress and ...
Alam M +3 more
europepmc +2 more sources
Neurokinin-1 Receptor Antagonists against Hepatoblastoma. [PDF]
Cancers (Basel), 2019 Hepatoblastoma (HB) is the most common malignant liver tumor that occurs during childhood. The prognosis of children with HB is favorable when a complete surgical resection of the tumor is possible, but for high-risk patients, the prognosis is much worse.
Muñoz M, Rosso M, Coveñas R.
europepmc +2 more sources
Current Medicinal Chemistry, 2021 The current standard of care in glioblastoma multiforme (GBM), as the most morbid brain tumor, is not adequate, despite substantial progress in cancer therapy.
Ali Motamed-Sanaye +2 more
exaly +2 more sources
Crystal structures of the human neurokinin 1 receptor in complex with clinically used antagonists
Nature Communications, 2019 Neurokinin receptors are G protein-coupled receptors. Here the authors present three crystal structures of the neurokinin 1 receptor (NK1R) in complex with small-molecule antagonists including aprepitant and netupitant and observe that these clinically ...
Jendrik Schöppe +6 more
doaj +2 more sources
Neurokinin-1 receptor antagonists in preventing postoperative nausea and vomiting: a systematic review and meta-analysis. [PDF]
Medicine (Baltimore), 2015 Newly developed neurokinin-1 receptor (NK-1R) antagonists have been recently tried in the prevention of postoperative nausea and vomiting (PONV). This systematic review and meta-analysis was conducted to explore whether NK-1R antagonists were effective ...
Liu M +6 more
europepmc +2 more sources
Exploring neurokinin-1 receptor antagonism for depression with structurally differentiated inhibitors [PDF]
Experimental and Molecular MedicineThe neurokinin-1 receptor (NK1R) has been investigated as a potential target for major depressive disorder owing to its role in stress regulation and neuroinflammation.
Hyeijung Yoo +8 more
doaj +2 more sources
Neurokinin pathway antagonists for vasomotor symptoms in women with breast cancer: focus on elinzanetant and fezolinetant [PDF]
BreastVasomotor symptoms (VMS) have a major impact on quality-of-life in women with hormone receptor–positive breast cancer receiving adjuvant endocrine therapy.
Katarzyna Pogoda +2 more
doaj +2 more sources